Monoclonal Gammopathy of Undetermined Significance.
Gonsalves WI, Rajkumar SV.
Ann Intern Med. 2022 Dec;175(12):ITC177-ITC192. doi: 10.7326/AITC202212200. Epub 2022 Dec 13.
Multiple myeloma.
van de Donk NWCJ, Pawlyn C, Yong KL.
Lancet. 2021 Jan 30;397(10272):410-427. doi: 10.1016/S0140-6736(21)00135-5.
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J, Valisekka SS, Hameed M, Bandi PS, Varma S, Onwughalu CJ, Ibrahim H, Mongia H.
Clin Lymphoma Myeloma Leuk. 2023 May;23(5):e195-e212. doi: 10.1016/j.clml.2023.02.004. Epub 2023 Feb 23.
Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options.
Amaador K, Peeters H, Minnema MC, Nguyen TQ, Dendooven A, Vos JMI, Croockewit AJ, van de Donk NWCJ, Jacobs JFM, Wetzels JFM, Sprangers B, Abrahams AC.
Neth J Med. 2019 Sep;77(7):243-254.
When a Monoclonal Gammopathy Is Not Multiple Myeloma.
Derman B, Castillo JJ, Sarosiek S, Beksac M.
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-10. doi: 10.1200/EDBK_349643.
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.
Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S.
Am J Hematol. 2021 Jul 1;96(7):846-853. doi: 10.1002/ajh.26155. Epub 2021 Mar 25.
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G.
Leukemia. 2020 Dec;34(12):3111-3125. doi: 10.1038/s41375-020-01051-x. Epub 2020 Oct 12.
Immune-Pathogenesis of Myeloma.
Dhodapkar MV.
Hematol Oncol Clin North Am. 2024 Apr;38(2):281-291. doi: 10.1016/j.hoc.2023.12.011. Epub 2024 Jan 8.
Neuropathies and paraproteins.
Lunn MP.
Curr Opin Neurol. 2019 Oct;32(5):658-665. doi: 10.1097/WCO.0000000000000726.
Cryptogenic stroke.
Fonseca AC, Ferro JM.
Eur J Neurol. 2015 Apr;22(4):618-23. doi: 10.1111/ene.12673. Epub 2015 Jan 18.
